Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BLL202202

SIRPα×PD-1 bsAb

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: SIRPα×PD-1 bsAb
    Indications: broad cancer
    Research phase: Ready for CMC development
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.



    Clear MoA



    1) Dual-blockade of PD-1 and SIRPα can activate potent antitumor effects via both innate and adaptive immune responses.


    2) Anti-SIRPα drugs are a potential treatment for solid cancer because they can more easily enter into the solid tumor microenvironment through binding to peripheral macrophages.


    3) SIRPα is only expressed on myeloid cells, not on erythrocytes. Unlike anti-CD47 drugs, Anti-SIRPα drugs do not cause erythrocytopenia.


    2. High affinity.


    The bsAb has high selectivity and high affinity to SIRPα and PD-1.
    The bsAb has high selectivity and high affinity to SIRPα and PD-1.


    3. The bsAb can bridge PD-1 and SIRPα positive cells, while single or combination of antibodies can’t.


    4. bsAb simultaneously release the inhibitory activity of DCs, T cells, and macrophages.


    5. Better anti-tumor activity in vivo.


    1) Excellent antitumor activity.


    2) Great tumor immune memory in tumor recurrence model.


    3) bsAb can polarize macrophages (decreased M2, increased M1) in the tumor microenvironment.


    6. CMC ready: high purity (SEC ≥ 99%), good stability, great druggability.

  • Project Introduction

    1. Asset type: SIRPα×PD-1 bsAb

    2. Indication: broad cancer

    4. Research phase: Ready for CMC development

    5. Cooperation demands:   License-out or co-development

    6. Research progress:

    a) CMC stage: pilot production and toxicity test.

    b) The bsAb binds specifically to SIRPα and PD-1 with high affinity.

    c) The combination of SIRPα and PD-1 shows better activity than solitary target in vivo and remains active in the recurrence model due to great immune memory.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message